 studi cyproheptadin treatment metastat carcinoid tumor malign carcinoid syndrom sixteen patient metastat neuroendocrin tumor malign carcinoid syndrom cyproheptadin periactin merck sharp dohm west point PA maximum toler dose mg usual side effect mild sedat dri mouth patient imposs treatment due nausea vomit patient signific relief diarrhea weight gain relief flush uncommon therapeut benefit cyproheptadin peripher effect acid excret patient case report object tumor regress cyproheptadin therapi patient cyproheptadin use therapeut tool manag diarrhea malign carcinoid syndrom appropri initi total daili dose mg/kg fraction prompt modif minim toler side effect